Tema Etfs LLC Buys 25,912 Shares of Gilead Sciences, Inc. $GILD

Tema Etfs LLC lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 72.9% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 61,440 shares of the biopharmaceutical company’s stock after acquiring an additional 25,912 shares during the period. Tema Etfs LLC’s holdings in Gilead Sciences were worth $6,820,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the stock. Rothschild Investment LLC grew its stake in shares of Gilead Sciences by 1.9% in the 2nd quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock valued at $503,000 after buying an additional 84 shares during the period. Hemington Wealth Management raised its stake in Gilead Sciences by 9.3% during the 3rd quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 85 shares during the period. Ignite Planners LLC boosted its holdings in Gilead Sciences by 1.1% in the third quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock worth $880,000 after acquiring an additional 86 shares in the last quarter. Archer Investment Corp grew its stake in Gilead Sciences by 1.2% in the second quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company’s stock valued at $807,000 after acquiring an additional 87 shares during the period. Finally, Binnacle Investments Inc increased its holdings in shares of Gilead Sciences by 14.3% during the second quarter. Binnacle Investments Inc now owns 702 shares of the biopharmaceutical company’s stock valued at $78,000 after acquiring an additional 88 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction on Monday, December 15th. The stock was sold at an average price of $122.00, for a total transaction of $366,000.00. Following the sale, the insider owned 106,221 shares in the company, valued at $12,958,962. This represents a 2.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction on Monday, December 29th. The shares were sold at an average price of $124.83, for a total value of $1,248,300.00. Following the completion of the transaction, the chief executive officer owned 566,698 shares of the company’s stock, valued at approximately $70,740,911.34. This trade represents a 1.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 136,257 shares of company stock valued at $16,855,192. 0.27% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

GILD has been the subject of several research reports. Wolfe Research reissued an “outperform” rating and issued a $150.00 price target on shares of Gilead Sciences in a research report on Monday, December 15th. Wall Street Zen raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 3rd. HSBC lifted their price objective on shares of Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a report on Wednesday, December 10th. Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday, October 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $135.00 price target on shares of Gilead Sciences in a research note on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $133.20.

Gilead Sciences Trading Up 0.4%

Shares of Gilead Sciences stock opened at $121.10 on Monday. The stock has a market capitalization of $150.25 billion, a P/E ratio of 18.78, a P/E/G ratio of 0.64 and a beta of 0.33. Gilead Sciences, Inc. has a 52-week low of $88.57 and a 52-week high of $128.70. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The stock’s 50-day simple moving average is $123.27 and its 200 day simple moving average is $117.67.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same quarter last year, the company earned $2.02 earnings per share. The company’s revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were issued a dividend of $0.79 per share. The ex-dividend date of this dividend was Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. Gilead Sciences’s payout ratio is presently 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.